Former ICMR Scientist: Only 7 Out Of Every 10 Lakh People May Face Clotting Risk Due To Covishield
Dr. Raman Gangakhedkar , a leading epidemiologist and former scientist at the Indian Council of Medical Research (ICMR), has emphasized that the risk of experiencing a rare side effect called thrombosis thrombocytopenia syndrome (TTS) after receiving the Covishield vaccine is extremely low, estimated at only seven to eight cases per one million vaccinated individuals. He has emphasized that individuals who have received this vaccine face "no risk at all" of encountering this side effect.
Gangakhedkar said, “the risk is highest when you get the first dose but it lowers with the second dose and is lowest with the third. If a side effect has to happen, it will show up within the initial two to three months.”
As per reports from UK media citing court documents, AstraZeneca, a major pharmaceutical company headquartered in the UK, has acknowledged that its Covid vaccine can rarely cause a side effect related to blood clots. The vaccine, called AZ Vaxzevria, is also manufactured by the Serum Institute of India (SII) and is known as Covishield . Covishield is used to vaccinate at least 90% of India's population.
Gangakhedkar said, “the risk is highest when you get the first dose but it lowers with the second dose and is lowest with the third. If a side effect has to happen, it will show up within the initial two to three months.”
As per reports from UK media citing court documents, AstraZeneca, a major pharmaceutical company headquartered in the UK, has acknowledged that its Covid vaccine can rarely cause a side effect related to blood clots. The vaccine, called AZ Vaxzevria, is also manufactured by the Serum Institute of India (SII) and is known as Covishield . Covishield is used to vaccinate at least 90% of India's population.
Next Story